Fundraising Fox
Bali Muralidhar
InvestorGlobal Head of Life Sciences & CIO at Abingworth
London
Writes $15M – $30M checks · typically $22.5M
Find your path to Bali
Sign up to see every warm intro you have to Bali
- Paths you didn't know you had: your email and LinkedIn already hold routes to Bali. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.
Contact· self-published, not guessed
Invests in
BiotechHealthtech
Deals · 4
AdvanCell IsotopesBoard seat
via Abingworth · filed Jul 2026 · $315M raise
Spruce BiosciencesBoard seat
via Abingworth · filed Oct 2025 · $50M raise
WugenBoard seat
via Abingworth · filed Jul 2021 · $37.2M raise
Onkure Therapeutics IncBoard seat
via Abingworth · filed Dec 2020 · $94.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Led
CymaBay Therapeutics
Board seats
AdvanCellAlloTeraAllotera TherapeuticsAscendPathalysR1 TxRheumaLogicsValnevaWilson Therapeutics
Investor
Allotera TherapeuticsAnjarium BiosciencesAscend Gene & Cell TherapiesCymabayCytospire TherapeuticsGlycomineNuCana BioMedOnboneReneo PharmaceuticalsWilson Therapeutics
Sources: the firm's website · SEC Form D filings · curated public sources.
Colleagues at Abingworth
Network5
Investors connected to Bali in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Bali Muralidhar?
- Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.
- Where does Bali Muralidhar work?
- Bali Muralidhar is Global Head of Life Sciences & CIO at Abingworth.
- What does Bali Muralidhar invest in?
- Bali Muralidhar invests in Biotech, Healthtech.
- What check size does Bali Muralidhar write?
- Bali Muralidhar typically writes checks of $15M – $30M.
- What boards does Bali Muralidhar sit on?
- Bali Muralidhar holds tracked board seats at AdvanCell, AdvanCell Isotopes, AlloTera, Allotera Therapeutics, Ascend, Onkure Therapeutics Inc, Pathalys, R1 Tx, RheumaLogics, Spruce Biosciences.
- What companies has Bali Muralidhar invested in?
- Investments tracked here include CymaBay Therapeutics, AdvanCell Isotopes, Allotera Therapeutics, Anjarium Biosciences, Ascend Gene & Cell Therapies, Cymabay, Cytospire Therapeutics, Glycomine, NuCana BioMed, Onbone, Reneo Pharmaceuticals, Spruce Biosciences, and 1 more.
- Does Bali Muralidhar lead rounds?
- Yes — Bali Muralidhar has led 1 tracked investment.
About this profile. Compiled from public sources — Abingworth's own website, regulatory filings and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights